Compare ADMA Biologics Inc (ADMA) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs PulteGroup, Inc. — how do they compare? ADMA Biologics Inc trades at $9.21 (market cap $2.13B), while PulteGroup, Inc. trades at $123.51 (market cap $24.75B). The key difference: PulteGroup, Inc. is far larger — about 11.6× ADMA Biologics Inc's market cap, and PulteGroup, Inc. pays a 0.8% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PHM | |
|---|---|---|
Market Cap | $2.13B | $24.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $142.56 |
52-Week Low | $7.60 | $108.00 |
Enterprise Value | $2.20B | $24.71B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
PulteGroup (PHM) trades at $129.92, down 2.81% on the day, amid mixed earnings performance with recent quarterly misses. The stock shows a bullish technical signal with strong moving averages and oversold RSI levels, while fundamentals reflect solid profitability with a 12.14% net margin and attractive valuation at a P/E of 12.71. Recent corporate developments include land acquisition for a new community, signaling growth initiatives.
The outlook is cautiously optimistic, supported by analyst consensus and a $144.17 price target, but risks include margin pressure from incentives and housing market sensitivity to interest rates. Investment appeal hinges on execution of margin recovery and sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
